- Home
- GRI vs ATXG Comparison
GRI vs ATXG Comparison
Compare GRI & ATXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- ATXG
- Stock Information
- Founded
- GRI 2018
- ATXG 2014
- Country
- GRI United States
- ATXG China
- Employees
- GRI N/A
- ATXG N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- ATXG Professional Services
- Sector
- GRI Health Care
- ATXG Consumer Discretionary
- Exchange
- GRI Nasdaq
- ATXG Nasdaq
- Market Cap
- GRI 3.4M
- ATXG 4.0M
- IPO Year
- GRI N/A
- ATXG N/A
- Fundamental
- Price
- GRI $1.80
- ATXG $0.64
- Analyst Decision
- GRI Strong Buy
- ATXG
- Analyst Count
- GRI 2
- ATXG 0
- Target Price
- GRI $22.00
- ATXG N/A
- AVG Volume (30 Days)
- GRI 143.8K
- ATXG 2.4M
- Earning Date
- GRI 08-13-2025
- ATXG 08-13-2025
- Dividend Yield
- GRI N/A
- ATXG N/A
- EPS Growth
- GRI N/A
- ATXG N/A
- EPS
- GRI N/A
- ATXG N/A
- Revenue
- GRI N/A
- ATXG $4,180,913.00
- Revenue This Year
- GRI N/A
- ATXG N/A
- Revenue Next Year
- GRI N/A
- ATXG N/A
- P/E Ratio
- GRI N/A
- ATXG N/A
- Revenue Growth
- GRI N/A
- ATXG N/A
- 52 Week Low
- GRI $1.10
- ATXG $0.49
- 52 Week High
- GRI $43.69
- ATXG $1.86
- Technical
- Relative Strength Index (RSI)
- GRI 65.05
- ATXG 46.61
- Support Level
- GRI $1.53
- ATXG $0.56
- Resistance Level
- GRI $1.75
- ATXG $0.68
- Average True Range (ATR)
- GRI 0.13
- ATXG 0.09
- MACD
- GRI 0.06
- ATXG 0.00
- Stochastic Oscillator
- GRI 89.55
- ATXG 18.83
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.